Pro Medicus Ltd (ASX: PME) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Pro Medicus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $10.83 billion
P/E Ratio 153.85
Dividend Yield 0.34%
Shares Outstanding 104.42 million
Earnings per share 0.667
Dividend per share 0.36
Year To Date Return 7.19%
Earnings Yield 0.65%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Pro Medicus Ltd (ASX: PME)
    Latest News

    A neon sign says 'Top Ten'.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX has bitterly disappointed investors today with a return to red territory.

    Read more »

    two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
    Share Gainers

    Why Bannerman, Clover, Polynovo, and Pro Medicus shares are pushing higher

    Not all shares are falling with the market on Tuesday. Here's why they are rising.

    Read more »

    Businessman smiles with arms outstretched after receiving good news.
    52-Week Highs

    5 ASX 300 shares smashing new 52-week highs on Tuesday

    Do you own any of these lucky shares today?

    Read more »

    A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
    Technology Shares

    Can you guess which ASX 200 tech share just hit a record high on a $140m contract win?

    This rapidly growing tech company has just won a huge contract.

    Read more »

    A young well-dressed couple at a luxury resort celebrate successful life choices.
    Opinions

    3 ASX shares that turned $100,000 into $1 million in 10 years or less

    Choose quality stocks representing companies with rapidly growing market share, and your millionaire dreams could come true.

    Read more »

    three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
    Investing Strategies

    3 ASX 200 stocks with absolutely no debt

    These businesses have excellent strength when it comes to their balance sheets.

    Read more »

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Growth Shares

    I found the most 'expensive', profitable ASX All Ords share: rip-off or bargain?

    A single number in isolation can be dangerous to an investor's decision making.

    Read more »

    A group of science or medical professionals cheering good news in the lab.
    Healthcare Shares

    One magnificent ASX share that turned $10,000 into $250,000

    It has been an astonishing journey for this winner.

    Read more »

    a man sits at his computer screen scrolling with his fingers with a satisfied smile on his face as though he is very content with the news he is receiving.
    How to invest

    The benefits of investing in 'platform' companies (and how to spot them on the ASX)

    Technology businesses that offer platforms can deliver strong returns according to this fund manager.

    Read more »

    busy trader on the phone in front of board depicting asx share price risers and fallers
    Broker Notes

    10 ASX 200 shares attracting buy ratings following their FY23 reports

    The experts are tipping share price growth for these companies following the release of their financial reports.

    Read more »

    Happy man holding Australian dollar notes, representing dividends.
    Dividend Investing

    Show us the money! The ASX shares delivering the best dividend upgrades this earnings season

    We reveal 12 ASX shares paying at least a 20% increase in dividends this August reporting season.

    Read more »

    A middle-aged couple dance in the street to celebrate their ASX share gains
    Dividend Investing

    Passive income watch: The ASX shares delivering the biggest dividend boosts this earnings season so far

    We identify 8 ASX shares delivering the best dividend increases this reporting season so far.

    Read more »

    Frequently Asked Questions

    Yes, the company historically pays two fully franked dividends a year. 

    Pro Medicus generally pays its shareholder dividends in March and October.

    Pro Medicus Ltd listed on the ASX on 10 October 2000.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    29 Feb 2024 $0.1800 100.00% Interim 22 Mar 2024
    06 Sep 2023 $0.1700 100.00% Final 28 Sep 2023
    02 Mar 2023 $0.1300 100.00% Interim 24 Mar 2023
    08 Sep 2022 $0.1200 100.00% Final 30 Sep 2022
    03 Mar 2022 $0.1000 100.00% Interim 25 Mar 2022
    09 Sep 2021 $0.0800 100.00% Final 01 Oct 2021
    04 Mar 2021 $0.0700 100.00% Interim 19 Mar 2021
    10 Sep 2020 $0.0600 100.00% Final 02 Oct 2020
    05 Mar 2020 $0.0600 100.00% Interim 20 Mar 2020
    12 Sep 2019 $0.0450 100.00% Final 04 Oct 2019
    12 Mar 2019 $0.0250 100.00% Special Cash 17 May 2019
    07 Mar 2019 $0.0350 100.00% Interim 22 Mar 2019
    06 Sep 2018 $0.0350 100.00% Final 27 Sep 2018
    08 Mar 2018 $0.0250 100.00% Interim 23 Mar 2018
    07 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    08 Sep 2016 $0.0150 0.00% Final 29 Sep 2016
    10 Mar 2016 $0.0150 0.00% Interim 24 Mar 2016
    15 Mar 2006 $0.0050 100.00% Special 05 Apr 2006
    15 Mar 2006 $0.0200 100.00% Interim 05 Apr 2006
    14 Sep 2005 $0.0050 100.00% Special Cash 04 Oct 2005
    14 Sep 2005 $0.0275 100.00% Final 04 Oct 2005
    16 Mar 2004 $0.0125 100.00% Interim 05 Apr 2004

    PME ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Pro Medicus Ltd

    Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

    Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.

    Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.

    PME Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $102.54 $1.87 1.86% 287,245 $101.36 $103.06 $101.27
    26 Mar 2024 $100.67 $0.77 0.77% 355,968 $98.66 $101.49 $98.23
    25 Mar 2024 $99.90 $3.70 3.85% 262,041 $96.07 $99.90 $95.70
    22 Mar 2024 $96.20 $-0.26 -0.27% 282,756 $96.19 $96.82 $95.57
    21 Mar 2024 $96.46 $0.44 0.46% 344,845 $95.95 $97.00 $95.56
    20 Mar 2024 $96.02 $-1.09 -1.12% 248,302 $97.45 $97.68 $96.00
    19 Mar 2024 $97.11 $-2.31 -2.32% 462,859 $99.11 $99.19 $96.50
    18 Mar 2024 $99.42 $2.15 2.21% 315,989 $97.26 $99.55 $96.91
    15 Mar 2024 $97.27 $-2.16 -2.17% 1,441,006 $98.12 $98.88 $96.09
    14 Mar 2024 $99.43 $-0.81 -0.81% 211,180 $99.97 $100.46 $98.91
    13 Mar 2024 $100.24 $0.73 0.73% 238,983 $100.25 $101.93 $99.80
    12 Mar 2024 $99.51 $0.38 0.38% 167,581 $98.88 $99.67 $98.06
    11 Mar 2024 $99.13 $-2.12 -2.09% 200,765 $98.79 $100.22 $98.08
    08 Mar 2024 $101.25 $2.88 2.93% 234,777 $99.49 $102.00 $99.25
    07 Mar 2024 $98.37 $-1.15 -1.16% 230,151 $99.99 $99.99 $97.33
    06 Mar 2024 $99.52 $-0.93 -0.93% 233,896 $99.87 $99.87 $97.98
    05 Mar 2024 $100.45 $0.74 0.74% 335,420 $99.60 $100.66 $97.85
    04 Mar 2024 $99.71 $-3.68 -3.56% 251,567 $103.40 $104.34 $99.61
    01 Mar 2024 $103.39 $-0.43 -0.41% 302,040 $102.00 $104.38 $101.70
    29 Feb 2024 $103.82 $1.82 1.78% 359,677 $101.23 $103.82 $100.61
    28 Feb 2024 $102.00 $2.10 2.10% 306,499 $98.40 $102.00 $98.01
    27 Feb 2024 $99.90 $0.55 0.55% 294,724 $98.92 $101.27 $97.62

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    21 Feb 2024 Alice Williams Buy 850 $74,681
    On-market trade.
    16 Feb 2024 Alice Williams Buy 810 $72,875
    On-market trade.
    27 Nov 2023 Alice Williams Buy 250 $22,510
    On-market trade.
    21 Nov 2023 Anthony Hall Sell 1,000,000 $88,020,000
    On-market trade.
    21 Nov 2023 Sam Hupert Sell 1,000,000 $88,020,000
    On-market trade.
    25 Aug 2023 Anthony Hall Transfer 70,000 $5,030,200
    Off-market transfer. non-cash, Estimated value

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Sam Aaron Hupert Chief Executive OfficerManaging Director Oct 2007
    Dr Hupert served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
    Mr Anthony Barry Hall Executive DirectorTechnology Director Jan 1983
    Mr Hall has been principal architect and developer of the core software systems.
    Mr Peter Terence Kempen Non-Executive ChairmanNon-Executive Director Mar 2008
    Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Board of St Hilda's College Ltd, University of Melbourne. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst and Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honours.
    Ms Alice Joan Morrice Williams Non-Executive Director Sep 2021
    Ms Williams is also a non-executive director of Vocus Group, Djerriwarrh Investments, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit and Risk Committee of Djerriwarrh Investments, ASC and Vocus Group and is a member of the Audit and Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Non-Executive member of the Foreign Investment Review Board. She is Chair of Risk committee and also serves on the People and Culture committee.
    Ms Deena Robyn Shiff Non-Executive Director Aug 2020
    Ms Shiff is also Chair of the Supervisory Board of Marley Spoon AG and is an Independent Member of the board of the Global Alliance for Vaccines and Immunisation, the multi-lateral global health fund based in Geneva. Deena is also on the board of Opera Australia. Previous board roles include Chairman of the global board of BAI Communications, Non-Executive Director of Appen, EOS Holdings and Director of the Citadel Group, Vice Chairman of the Government's Export Credit Agency EFIC, as well as board roles in several venture capital backed growth stage ICT companies. She is Chair of the People and Culture committee and serves on the Risk committee.
    Mr Anthony James Glenning Non-Executive Director May 2016
    Mr Glenning is the fund manager of Skalata Ventures, investing in early-stage companies to help them scale and grow into sustainable businesses. He is a Director of Austco Healthcare since September 2018, an international provider of healthcare communication and clinical workflow management solutions. Anthony is also a Director of Iress since October 2022, a technology company providing software to the financial services industry. Anthony has previously been Chairman of Cyrise Pty Ltd, an accelerator for early-stage cyber security start-ups and Investment Director of Starfish Ventures and was the founder and previously the CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He also serves on the People and Culture committee and Risk committee.
    Dr Leigh Bernard Farrell Non-Executive Director Sep 2017
    Dr Farrell is the Head of Health Security Systems Australia, a Division of DMTC, Managing Director of AdNED Pty, non-executive director of both Ena Respiratory Pty and Axelia Oncology Pty, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialisation Committee, a member of the Independent Advisory Council of Medicines Australia, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins, Chair of the Scientific Advisory Board of Island Pharmaceuticals Ltd and is a member of the National Measurement Institute Mask Testing Forum. Leigh was previously Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. She also serves on the People and Culture committee and Risk committee.
    Ms Danny English Company Secretary Mar 2023
    -
    Clayton Hatch Chief Financial Officer
    -
    Nick Peace Chief Strategy Officer
    -
    Danny English Company Secretary
    -
    Danny Tauber General Manager Australia
    -
    Malte Westerhoff General Manager Europe and Global Chief Technology Officer
    -
    Brad Levin General Manager North America and Global Head of Marketing
    -
    Teresa Gschwind Global Head of Customer Service
    -
    Sean Lambright Global Head of Sales
    -
    Sharni Redenbach People and Culture Director
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr S Hupert (multiple shareholdings) 26,137,660 25.03%
    Mr A Hall (multiple shareholdings) 26,109,000 25.00%
    HSBC Custody Nominees (Australia) Limited 15,568,938 14.91%
    J P Morgan Nominees Australia Limited 7,320,773 7.01%
    Citicorp Nominees Pty Ltd 6,911,271 6.62%
    National Nominees Limited 1,951,517 1.87%
    BNP Paribas Noms Pty Ltd 1,247,848 1.19%
    Mr Peter Terence Kempen and Mrs Elaine Margaret Kempen (multiple shareholdings) 629,082 0.60%
    Citicorp Nominees (Colonial First State) 605,943 0.58%
    Mr Bram Vander Jagt and Mrs Maaike Vander Jagt 480,000 0.46%
    Grain Exporters (Australia) Pty Ltd 479,000 0.46%
    Mr Michael Wu 429,244 0.41%
    Mr Danny Tauber 290,876 0.28%
    Mr Stephen Geoffrey Wilson and Ms Denise Adele Prandi 285,037 0.27%
    Mr Colin Gregory Organ 271,000 0.26%
    Mr John Charles Plummer 250,000 0.24%
    Mr Kenneth John Vander Jagt and Mrs Tanya Vander Jagt 208,159 0.20%
    Mr Roderick Lyle 190,000 0.18%
    Mr Sean Michael Lambright 179,039 0.17%
    Mr Evan Philip Clucas and Ms Leanne Jane Weston 158,980 0.15%

    Profile

    since

    Note